|
|
|||
|
| |||
|
| |||
|
| |||
|
|
|||
|
Gang-Shi Wang, Meng-Wei Wang, Ben-Yan Wu, Xin-Yan Yang, Wei-Hua Wang, Wei-Di You, Department of Gerontal Gastroenterology, General Hospital of Chinese PLA, Beijing 100853, China Supported by the Key Project from the 10th Five-year Plan of Chinese PLA, No. 01Z035, and International Cooperation Project from the 11th Five-year Plan of Chinese PLA, No. 06H044 Correspondence to: Dr. Gang-Shi Wang, Department of Gerontal Gastroenterology, General Hospital of Chinese PLA, Beijing 100853, China. wanggangshi@hotmail.com Telephone: +86-10-66937393 Fax: +86-10-66937393 Received: August 2, 2007 Revised: October 9, 2007
Abstract AIM: To analyze the expression profiles of a human gastric-cancer-related gene, GCRG123, in human gastric signet-ring cell carcinoma tissues, and to perform bioinformatics analysis on GCRG123.
METHODS: In situ hybridization was used to explore the GCRG123 expression pattern in paraffin-embedded gastric tissues, including 15 cases of signet-ring cell carcinoma, 15 of intestinal-type adenocarcinoma, and 15 of normal gastric mucosa. Northern blotting was used to analyze the differences in GCRG123 expression between stomach signet-ring cell carcinoma and intestinal-type adenocarcinoma tissues. Online software, including BLAST, Multalin and BLAT, were applied for bioinformatics analysis. National Center for Biotechnology Information (NCBI) and the University of California Santa Cruz (UCSC) databases were used for the analyses.
RESULTS: The in situ hybridization signal appeared as blue precipitates restricted to the cytoplasm. Ten out of 15 cases of gastric signet ring cell carcinoma, normal gastric mucosal epithelium and pyloric glands showed high GCRG123 expression. Low GCRG123 expression was observed in gastric intestinal-type adenocarcinoma and normal gastric glands. Northern blotting revealed that GCRG123 was up-regulated in signet-ring cell carcinoma tissue but down-regulated in intestinal-type adenocarcinoma tissue. BLAST and Multalin analyses revealed that the GCRG123 sequence had 92% similarity with the ORF2 sequence of human long interspersed nuclear element retrotransposons (LINE-1, L1). BLAT analysis indicated that GCRG123 mapped to all chromosomes. GCRG123 was found to integrate in the intron-17 and -23 of Rb, 5’ flanking region of IL-2 and clotting factor Ⅸ genes.
CONCLUSION: GCRG123, an active member of the L1 family, was up-regulated in human gastric signet-ring cell carcinoma.
© 2008 WJG. All rights reserved.
Key words: Stomach; Signet-ring cell carcinoma; GCRG123; LINE-1; In situ hybridization; Bioinformatics
Peer reviewers: Hiroki Nakamura, MD, Department of Gastroenterology and Hepatology, 1-1-1, Minami Kogushi, Ube, Yamaguchi 755-8505, Japan; Giuseppe Brisinda, MD, Department of Surgery, Catholic School of Medicine “Agostino Gemelli”, Largo Agostino Gemelli 8-00168 Rome, Italy
Wang GS, Wang
MW, Wu BY, Yang XY, Wang WH, You WD. LINE-1 family member GCRG123 gene
is up-regulated in human gastric signet-ring cell carcinoma. World J
Gastroenterol 2008; 14(5): 758-763 Available from: URL: http://www.wjgnet.com/
INTRODUCTION Gastric cancer remains one of the most common forms of cancer worldwide with approximately 870 000 new cases and 650 000 deaths per year[1-4], which accounts for about 9.9% of new cancers[5]. Worldwide, there has been a decline in the incidence of the intestinal type gastric cancer in the last few decades, following the overall decline in the incidence of gastric cancer. By contrast, the decline in the diffuse type gastric cancer has been more gradual. Some studies have reported an increase in the diffuse type of gastric carcinoma, especially the signet-ring cell type[6]. As a result, the diffuse type now accounts for about 30% of gastric carcinomas in some reported series[7]. Intestinal-type and diffuse-type gastric cancer differ in their epidemiology, pathogenesis, genetic profile, and clinical outcome[8]. In 1999, we cloned a gene segment GCRG123, which was down-regulated in gastric adenocarcinoma. BLASTX analysis revealed that the predicted GCRG123 product was a lamin-like protein[9]. Recently, we have used the updated GeneBank database for further analysis on the GCRG123 sequence. We found that GCRG123 appeared to be a long interspersed nucleotide element-1 (LINE-1, L1) family member. Additionally, we revealed that GCRG123 was ultimately up-regulated in stomach signet-ring cell carcinoma, as well as in normal pyloric glands and epithelia, which shows an opposite expression pattern compared with its down-regulation in stomach intestinal-type adenocarcinoma.
MATERIALS AND METHODS Patients and tissue acquisition All samples were obtained from the Department of Pathology, General Hospital of Chinese PLA. Specimens of paraffin-embedded gastric tissues, including 15 cases of gastric signet-ring cell carcinoma, 15 of advanced gastric intestinal-type adenocarcinoma and 15 of normal gastric mucosal tissues, were collected for in situ hybridization analysis. One set of fresh gastric signet-ring cell carcinomas and paired non-cancerous gastric tissues, and one set of fresh gastric intestinal-type adenocarcinomas and paired non-cancerous gastric tissues were used for Northern blot analysis. The diagnosis of cancer was confirmed through histology.
In situ hybridization cRNA probe labeling: Digoxigenin-labeled anti-sense and sense cRNA probes were prepared by in vitro transcription (DIG RNA Labeling Kit (SP6/T7); Roche Diagnostics, Mannheim, Germany). Briefly, the following labeling procedure was employed: purified GCRG123 cDNA 100 ng/10 mL, 5 × NTP labeling mixture 4 mL, 5 × transcription buffer 4 mL, and RNA polymerase SP6/T7 2 mL were mixed gently, centrifuged, and then incubated for 1 h at 42℃. Two microliters of RNase-free DNase I was added to remove template DNA, by incubating for 15 min at 37℃, and the reaction was finally stopped by adding 2 mL 0.2 mol/L EDTA (pH 8.0). Labeling efficiency was directly detected by a spot test as described in the protocol of the kit.
Hybridization: All specimens were fixed in 10% neutral-buffered formalin and embedded in paraffin. A series of 5-mm thick sections were cut for analysis. In situ hybridization was performed as previously described[10,11] with some amendments, using digoxigenin-labeled anti-sense cRNA probes. Briefly, the slides were dried at 40℃ overnight, dewaxed, rehydrated and pretreated with DEPC-treated PBS containing 100 mmol/L glycine and 0.3% Triton X-100, respectively. The sections were then permeabilized with 20 mg/mL RNase-free proteinase K (Merck, Darmstadt, Germany) for 20 min, incubated at 37℃ for at least 20 min with prehybridization buffer. Each section was overlaid with 30 mL hybridization buffer containing 10 ng digoxigenin-labeled cRNA probe and incubated at 42℃ overnight. After hybridization, the section was incubated with digoxigenin antibody (75 mU/mL) for 2 h. The positive signal for GCRG123 mRNA was detected by using NBT/BCIP (Promega, WI, USA) as a substrate. Sense cRNA probes were used as a negative control. The presentation of blue staining in the cytoplasm was considered positive. The positive staining of cytoplasm was scored manually as described below: -, barely detectable light blue; 1+, diffuse light blue; 2+, blue; 3+, dark blue. More than 100 non-tumor or tumor cells were quantified in each measurement, and more than one measurement was required to confirm the diagnosis. Consequent slides with H&E staining were then reviewed to compare the histological patterns to the staining patterns in the in situ hybridization preparations.
Northern blot analysis Dig Northern Starter Kit (Roche Diagnostic, Indianapolis, IN, USA) was used. The procedure of hybridization was performed according to the manufacturer’s protocol. Digoxigenin-labeled cRNA probe was generated as described above. Digoxigenin-labeled sense cRNA probe was used as a negative control. The hybridization signals were visualized with chemiluminescence, which was recorded on X-ray films. The exposure time was 10 min.
Bioinformatic analysis BLAST (http://www.ncbi.nlm.nih.gov/BLAST/)[12] was used for sequence similarity search. MultAlin (http://bioinfo.genopole-toulouse.prd.fr/multalin/multalin.html)[13] was used for multiple sequence alignment analysis. BLAT (http://genome.ucsc.edu/cgi-bin/hgBlat) was applied to find the genomic coordinates of mRNA, and to search for gene family members[14]. Alignment parameters were set as default. NCBI and UCSC databases were used for the analyses.
Informed consent The study protocol was approved by the Institutional Review Board of the hospital under the guidelines of the 1975 Declaration of Helsinki. Written informed consent was obtained from all patients.
RESULTS In situ hybridization
GCRG123
expression was analyzed at the mRNA level using in situ
hybridization. The hybridization signal appeared as blue staining in the
cytoplasm. Fourteen gastric intestinal-type adenocarcinoma cases showed
- to ± staining (Figure 1A).
Northern blotting Both normal gastric tissue and signet-ring cell carcinoma tissue showed strong hybridization signals, while the gastric intestinal-type carcinoma tissue showed a weak signal. These results seem to indicate that GCRG123 expression was higher in gastric signet-ring cell carcinoma than in intestinal-type adenocarcinoma (Figure 2).
Bioinformatic analysis The sequence of GCRG123 was enrolled for a sequence-similarity search in the GenBank database. GCRG123 shared 92% similarity with the human transposon L1 (M80343) sequence, as well as the highly active L1 sequence reported in the literature[15]. Multalin analysis revealed that GCRG123 was located at nucleotides 2767-3215 of L1, at which the L1 ORF2 dwells (Figure 3). GCRG123 was found to integrate in intron-17 and -23 of Rb (L11910), the 5’ flanking region of IL-2 (Ⅹ67285), and the 5’ flanking region of clotting factor Ⅸ (Ⅹ75349) genes (GenBank accession numbers in parentheses). BLAT analysis showed that GCRG123 mapped to all the human chromosomes.
DISCUSSION Our previous bioinformatic analysis of GCRG123 showed that the predicted peptide sequence of GCRG123 has 80% homology with a human lamin-like protein (GenBank accession number, AAA36178)[9], therefore, we predicted that GCRG123 might be a gene that encoded a lamin-like protein. However, the results of the present study indicate that GCRG123 tends to be an active LINE-1 family member. Retrotransposable elements, such as L1, Alu and endogenous retroviruses, make up some 45% of human DNA[16]. L1 is one of the most successful retrotransposons and occupies 17% of DNA[17]. In the early stages, because of the lack of any obvious correlation with cellular functions, retrotransposable elements were considered to be mere remnants of our genetic evolution and given the name ‘‘junk DNA’’[18]. However, recent data have revealed that some L1s do remain retrotransposition-competent. It has been shown that L1 is a functionally capable gene. For example, human embryonic stem cells can express endogenous L1 elements[19]. L1 can retrotranspose in neuronal precursors, and can consequently alter the expression of neuronal genes, which in turn, can influence neuronal cell fate in vitro[20]. L1 retrotransposition can also occur in non-dividing somatic cells[21]. A retrotransposition-competent, functional L1 element covers about 6.1 kb and contains a 5’ untranslated region, a 1-kb ORF1 that encodes a protein (p40) with RNA-binding ability, followed by a 3.8-kb ORF2 that codes for a protein (p150) with endonuclease and reverse transcriptase (RT) activities, and a cysteine-histidine-rich domain. The 3’ end of L1 is terminated by a short 3’ untranslated region and a poly(A) tail[22-26]. L1 likely integrates into the genomic DNA by a process called target primed reverse transcription and shapes mammalian genomes through many different ways, such as retrotransposition, transduction and gene expression alteration[27]. Although the overwhelming majority of L1s (about 99.8%) are inactive because of 5’ truncations, internal rearrangements and mutations, 80-100 retrotransposition-competent L1s have been predicted in humans. Remarkably, 84% of the retrotransposition capability of these elements has been shown to be present in six highly active L1s[15]. It has been proposed that retrotransposons modulate the expression of specific genes through a transcriptional interference-based mechanism. To exert such effect on neighboring genes, retrotransposons need not necessarily be full-length, nor retrotransposition-competent, but simply endowed with functional promoter elements[28]. Previous studies have shown that some non-full length L1 elements (even shorter than 500 bp) may yield L1 products such as L1 RNA or active RT[29-31]. L1 RNAs are also involved in extensive RNA splicing that can radically alter the diversity of expressed RNA forms from these elements, as well as influence their impact on gene expression upon genomic insertion[32]. The state-of-the-art understanding of L1 described above prompted us to propose that GCRG123 may be an active L1 family member, as supported by our findings. First, the GCRG123 sequence shared 92% homology with the conserved sequence of the highly active L1s (hot L1s). Second, GCRG123 can map to all chromosomes, which is similar to L1s. Third, GCRG123 can integrate in the intron or 5’ flanking region of some known genes, which suggests that it has the potential to adjust the function of these genes. Finally, in situ hybridization and Northern blot analysis at the mRNA level showed a distinct GCRG123 expression pattern in different kinds of gastric mucosa cells. A lot of evidence has indicated that L1 is involved in a wide spectrum of diseases, including cancer[28,33,34]. In colon cancer, the APC gene can be disrupted by somatic insertion of an L1 sequence into the last exon of the gene[35]. Takai et al have found that hypomethylation of L1 is detected in human hepatocellular carcinoma, but never in the surrounding liver tissues, whether or not liver cirrhosis is present[36]. Hypomethylation of L1 has also been revealed in urothelial carcinoma and prostate adenocarcinoma[37-39]. In malignant cells, there is a direct correlation between the hypomethylation of 5’ L1 sequences and the presence of L1 proteins, which suggests that elements with hypomethylated 5’ ends are transcriptionally active[40]. The hypomethylation of repetitive elements in cancer is directly linked to the neoplastic process and not a simple consequence of loss of growth control[41]. Previous studies have shown that L1 is essential for the proliferation of tumor cells. The functional knock-out of LINE-1 expression by RNAi reduces the proliferation and promotes the differentiation of tumorigenic human cells[29,42]. Up till now, no data about the relationship between L1 and stomach cancer have been reported. The present study on the distinct expression pattern of GCRG123 in gastric signet-ring cell carcinoma may be the first to link an L1 family member to stomach oncogenesis. During previous decades, several histological classification systems, such as those of Lauren, Nakamura and Ming, have been widely used for gastric adenocarcinoma. These systems agree that the intestinal/differentiated/expending type and diffuse/undifferentiated/infiltrative type differ greatly in terms of epidemiology, pathogenesis, genetic profile, and clinical outcome[8,43-46]. Signet-ring cell carcinoma belongs to the diffuse/undifferentiated/infiltrative type group. Nakamura has indicated that the morphological findings of undifferentiated type carcinoma under light and electron microscopy are similar to both the mucous cells of pyloric crypts and pyloric gland cells[44]. Interestingly, our study found that GCRG123 was over-expressed in pyloric gland cells, epithelia (surface mucous cells) and signet-ring cells, which correlated with Nakagawa’s description of undifferentiated carcinoma. The distinct GCRG123 expression patterns in intestinal-type adenocarcinoma and signet-ring cell carcinoma also support the concept that these two types of carcinoma have different genetic profiles. GCRG123 is over-expressed simultaneously in gastric epithelia, pyloric glands and signet-ring cell carcinoma, therefore, we believe that GCRG123 might be closely associated with gastric mucous secretion. Further studies are required to confirm this speculation.
COMMENTS Background Evidence indicates that a retrotransposition-competent, functional L1 element is involved in a wide spectrum of diseases, including cancer. A previous study has shown that a gene segment GCRG123 is down-regulated in human gastric intestinal-type adenocarcinoma. Intestinal- and diffuse-type gastric cancers differ in their epidemiology, pathogenesis, genetic profile and clinical outcome.
Research frontiers To modulate the expression of specific genes, retrotransposons, such as L1, need not necessarily be full-length, nor retrotransposition-competent, but simply endowed with functional promoter elements. Some non-full length L1 elements could yield L1 products such as L1 RNA or active RT. L1 is essential for the proliferation of tumor cells. The functional knock-out of L1 expression reduces cell proliferation and promotes cell differentiation.
Innovations and breakthroughs GCRG123 may be an active L1 family member, because of its sequence homology with the conserved sequence of the highly active L1s and its integration in the intron or 5’ flanking region of some known genes. In situ hybridization and Northern blot analysis showed that GCRG123 was up-regulated in signet-ring cell carcinoma. Besides, GCRG123 was also over-expressed in normal gastric epithelia and pyloric glands. The present study possibly represents the first to link an L1 family member to stomach oncogenesis.
Applications Updated knowledge about L1 shifts the focus from protein-coding genes to repeated retroelements as mediators of abnormal biological processes. Functional L1 family members may be regarded as promising targets in the development of novel, differentiation-inducing approaches to cancer therapy. The distinct expression pattern of GCRG123 in gastric signet-ring cell carcinoma may provide a new area to further understand the genetic characteristics of gastric signet-ring cell carcinoma.
Terminology LINE-1: highly repeated sequences, 6-8 K base pairs in length, which contain RNA polymerase II promoters. They also have an ORF that is related to the RT of retroviruses, but they do not contain long terminal repeats. Copies of the LINE 1 (L1) family form about 17% of the human genome.
Peer review This is an interesting article. The title reflects the major contents of the article. The abstract gives a clear delineation of the research background, objectives, materials and methods, results and conclusions. The methods are innovative and systematic. A detailed description has been provided. The results provide sufficient experimental evidence or data from which scientific conclusions can be drawn. The discussion is well organized and an overall theoretical analysis is given. The most current literature is cited. Overall, a it is well-written and well-researched article.
REFERENCES 1 Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108 PubMed
2
Lau M, Le A, El-Serag HB. Noncardia gastric adenocarcinoma
remains an important and deadly cancer in the United 3 Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol 2006; 12: 354-362 PubMed 4 Kelley JR, Duggan JM. Gastric cancer epidemiology and risk factors. J Clin Epidemiol 2003; 56: 1-9 PubMed 5 Parkin DM. Epidemiology of cancer: global patterns and trends. Toxicol Lett 1998; 102-103: 227-234 PubMed
6
Henson DE, Dittus C, Younes M, Nguyen H, Albores-Saavedra J. Differential trends
in the intestinal and diffuse types of
7
Ikeda Y, Mori M, Kamakura T, Haraguchi Y, Saku M, Sugimachi K.
Improvements in diagnosis have changed the
8
Hamilton JP, Meltzer SJ. A review of the genomics of gastric
cancer. Clin Gastroenterol Hepatol 2006; 4: 416-425
9
Wang G, Wang M, Wu B, You W. A lamin-like protein gene is
down-regulated in human gastric cancer. Zhonghua Yixue
10
Komminoth P. Digoxigenin as an alternative probe labeling for in
situ hybridization. Diagn Mol Pathol 1992; 1: 142-150
11
Komminoth P, Merk FB, Leav I, Wolfe HJ, Roth J. Comparison of
35S- and digoxigenin-labeled RNA and oligonucleotide
12
Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local
alignment search tool. J Mol Biol 1990; 215: 403-410
13 Corpet F. Multiple sequence alignment with hierarchical clustering. Nucleic Acids Res 1988; 16: 10881-10890 PubMed 14 Kent WJ. BLAT--the BLAST-like alignment tool. Genome Res 2002; 12: 656-664 PubMed
15
Brouha B, Schustak J, Badge RM, Lutz-Prigge S, Farley AH, Moran
JV, Kazazian HH Jr. Hot L1s account for the bulk of
16
Deininger PL, Moran JV, Batzer MA, Kazazian HH Jr. Mobile
elements and mammalian genome evolution. Curr Opin
17
Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J,
Devon K, Dewar K, Doyle M, FitzHugh W, Funke R, 18 Orgel LE, Crick FH. Selfish DNA: the ultimate parasite. Nature 1980; 284: 604-607 PubMed
19
Garcia-Perez JL, Marchetto MC, Muotri AR, Coufal NG, Gage FH,
O'Shea KS, Moran JV. LINE-1 retrotransposition in
20
Muotri AR, Chu VT, Marchetto MC, Deng W, Moran JV, Gage FH.
Somatic mosaicism in neuronal precursor cells
21
Kubo S,
Seleme MC, Soifer HS, Perez JL, Moran JV, Kazazian HH Jr, Kasahara N. L1
retrotransposition in nondividing and
22
McMillan JP, Singer MF. Translation of the human LINE-1 element,
L1Hs. Proc Natl Acad Sci USA 1993; 90: 11533-
23
Singer MF,
Krek V, McMillan JP, Swergold GD, Thayer RE. LINE-1: a human
transposable element. Gene 1993; 135:
24
Moran JV, Holmes SE, Naas TP, DeBerardinis RJ, Boeke JD, Kazazian
HH Jr. High frequency retrotransposition in
25 Feng
Q, Moran JV, Kazazian HH Jr, Boeke JD. Human L1 retrotransposon
encodes a conserved endonuclease required for
26
Hohjoh H, Singer MF. Sequence-specific single-strand RNA binding
protein encoded by the human LINE-1 27 Ostertag EM, Kazazian HH Jr. Biology of mammalian L1 retrotransposons. Annu Rev Genet 2001; 35: 501-538 PubMed
28
Sinibaldi-Vallebona P, Lavia P, Garaci E, Spadafora C. A role for
endogenous reverse transcriptase in tumorigenesis
29
Kuo KW, Sheu HM, Huang YS, Leung WC. Expression of transposon
LINE-1 is relatively human-specific and function of
30
Boissinot S,
Entezam A, Furano AV. Selection against deleterious LINE-1-containing
loci in the human lineage. Mol Biol
31
Liu J, Nau MM, Zucman-Rossi J, Powell JI, Allegra CJ, Wright JJ.
LINE-I element insertion at the t(11;22) translocation
32
Belancio VP, Hedges DJ, Deininger P. LINE-1 RNA splicing and
influences on mammalian gene expression. Nucleic Acids
33
Schulz WA, Steinhoff C, Florl AR. Methylation of endogenous human
retroelements in health and disease. Curr Top
34
Druker R, Whitelaw E. Retrotransposon-derived elements in the
mammalian genome: a potential source of disease. J
35
Miki Y, Nishisho I, Horii A, Miyoshi Y, Utsunomiya J, Kinzler KW,
Vogelstein B, Nakamura Y. Disruption of the APC gene by
36
Takai D, Yagi Y, Habib N, Sugimura T, Ushijima T.
Hypome-thylation of LINE1 retrotransposon in human hepatocellular
37
Laner T,
Schulz WA, Engers R, Muller M, Florl AR. Hypomethylation of the XIST
gene promoter in prostate cancer. Oncol
38
Cho NY, Kim BH, Choi M, Yoo EJ, Moon KC, Cho YM, Kim D, Kang GH.
Hypermethylation of CpG island loci and
39
Florl AR, Lower R, Schmitz-Drager BJ, Schulz WA. DNA methylation
and expression of LINE-1 and HERV-K provirus
40
Alves G,
Tatro A, Fanning T. Differential methylation of human LINE-1
retrotransposons in malignant cells. Gene 1996;
41
Perrin D, Ballestar E, Fraga MF, Frappart L, Esteller M, Guerin
JF, Dante R. Specific hypermethylation of LINE-1 elements
42
Sciamanna I, Landriscina M, Pittoggi C, Quirino M, Mearelli C,
Beraldi R, Mattei E, Serafino A, Cassano A, Sinibaldi-
43
Lauren P. Histogenesis of intestinal and diffuse types of gastric
carcinoma. Scand J Gastroenterol Suppl 1991; 180:
44
Nakamura K, Sugano H, Takagi K, Kumakura K. Histogenesis of
cancer of the stomach, with special reference to light 45 Ming SC. Gastric carcinoma. A pathobiological classification. Cancer 1977; 39: 2475-2485 PubMed
46
Tian MM, Zhao AL, Li ZW, Li JY. Phenotypic classification of
gastric signet ring cell carcinoma and its relationship with
S- Editor Piscaglia AC L- Editor Kerr C E- Editor Liu Y
| |||
|
|
PubMed